Company Description
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).
To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections.
In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed.
It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine’s broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases.
Similarly, our fully human monoclonal antibody, F598, that also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials.
We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU).
Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation.
| Country | United States |
| Founded | 2006 |
| Industry | Health Care |
| Sector | Biotechnology |
| CEO | Daniel R. Vlock |
Contact Details
Address: 186 Alewife Brook Pkwy #1068 Cambridge, MA 02138 United States | |
| Phone | (617) 780-1598 |
| Website | alopexx.com |
Stock Details
| Ticker Symbol | ALPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001880995 |
| Employer ID | 86-3959763 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel R Vlock, MD | President, Chief Executive Officer and Director |
| Thomas T. Thomas | Chief Financial Officer |
| Gerald B. Pier, PhD | Chief Scientific Officer |
| William W. Chin, MD | Senior Strategic Advisor, Director |
| Christine de los Reyes, PharmD, MBA | Chief Business Officer, Chief Commercialization Officer |
| Peter J. Werth | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 8, 2025 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Mar 14, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 27, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Feb 1, 2023 | FWP | Free Writing Prospectus |
| Feb 1, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 15, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 18, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Oct 7, 2022 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |